Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun CC, Woyach JA. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025 Sep 11; 146(11):1276-1285.

Rizzo A, Zayed A, Vitale E, Buti S, Takeshita H, Crabb S, Roviello G, Seront E, Tapia JC, Scagliarini S, Popovic L, Kopp RM, Abahssain H, Rizzo M, Monteiro FSM, Massafra R, Brunetti O, Santini D, Ürün Y, Montironi R, Mollica V, Massari F, Soares A, Santoni M. Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset. Clin Exp Metastasis. 2025 Sep 06; 42(5):52.

Weis AM, Bauer KM, Tang WW, Stephen-Victor E, Bell R, Brown DG, Ekiz HA, Tran V, Klag KA, Swanson EA, Barrios L, Harwood M, Hill JH, Ost KS, Gigic B, Schneider M, Ose J, Hardikar S, Toriola AT, Shibata D, Li CI, Figueiredo JC, Byrd DA, Siegel EM, Arnolds K, Lozupone C, Ulrich CM, O'Connell RM, Stephens WZ, Round JL. A capsular polysaccharide from a healthy human microbiota member activates a Lag-3-NK cell axis to restrain colon cancer and augment immunotherapy. Cell Rep. 2025 Sep 23; 44(9):116172.

Narikawa Y, Kuramasu A, Hosonuma M, Murayama M, Funayama E, Sasaki A, Baba Y, Toyoda H, Isobe J, Tajima K, Nakashima R, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Tsurui T, Hirasawa Y, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Horiike A, Kobayashi S, Tsunoda T, Kobayashi S, Kobayashi H, Oguchi T, Shimane T, Kiuchi Y, Yoshimura K. Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. Cancer Immunol Immunother. 2025 Aug 19; 74(9):289.

Murray AM, Swingle KL, Mitchell MJ. Engineering Nanoparticles for Gynecologic Cancer Therapy. ACS Nano. 2025 Sep 02; 19(34):30758-30785.

Silbert SK, Rankin AW, Hoang CN, Semchenkova A, Myers RM, Zerkalenkova E, Wang HW, Kovach AE, Yuan CM, Delgado Colon D, Vasseur L, Bataller A, John S, Utley Lyons K, Friedes B, Alonso-Saladrigues A, Abdel-Azim H, Balducci E, Aljudi AA, Balsat M, Biery DN, Chamdin A, Chang BH, Cuevo RS, De Moerloose B, Dickens DS, Duffner U, Duployez N, El Chaer F, Elliott MA, Escherich G, Fernandes S, Fitzjohn MR, Gahvari Z, Grupp SA, He RR, Harrison C, Hergott CB, Hsieh EM, Kim AS, Kuo DJ, Larson DP, Lee BJ, Leguay T, Lindsley RC, Mangaonkar AA, Mezger K, Pacenta HL, Pan J, Provost M, Puri L, Raikar SS, Martinez A, Bristol I, Murphy K, Reiman L, Redell M, Reed K, Roth-Guepin G, Rubinstein J, Savasan S, Schafernak K, Stevens A, Talleur A, Torres Carapia N, Vargaftig J, Vatsayan A, Wölfl M, Zhao L, Rives S, Fabrizio VA, Sasaki K, Aldoss I, Boissel N, Rheingold SR, Davis KL, Ghorashian S, Jacoby E, Popov A, Lamble AJ, Shah NN. Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood. 2025 Jul 24; 146(4):437-455.

Stopeck AT, Abu-Khalaf M, Borges V, Chmielowski B, Rao R, Xie B, Dudek AZ, Mina L, O'Shaughnessy J, Chisamore M, Mattson P, Gargano M, Cox J, Osterwalder B, Drees J, Harrison B, Chan ASH, Qiu X, Ottoson N, Bose N, Uhlik M, Graff J, Iglesias J. Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy. J Immunol. 2025 Jul 01; 214(7):1529-1538.

Sun NY, Kumar S, Kim YS, Varghese D, Mendoza A, Nguyen R, Okada R, Reilly K, Widemann B, Pommier Y, Elloumi F, Dhall A, Taniyama D, Patel M, Aber E, Contreras CF, Kaplan RN, Kiseljak-Vassiliades K, Wierman ME, Martinez D, Pogoriler J, Hamilton AK, Diskin SJ, Maris JM, Robey RW, Gottesman MM, Del Rivero J, Roper N. Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma. Nat Commun. 2025 Jul 01; 16(1):5511.

Seidel JA, Alder L, Salama AKS, Anders CK, Komisarow J, Fecci PE, Sperduto P, Mullikin T, Kirkpatrick JP, Floyd SR, Reitman ZJ, Vaios EJ. Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade. J Neurooncol. 2025 Oct; 175(1):199-208.

Monette A, Aguilar-Mahecha A, Altinmakas E, Angelos MG, Assad N, Batist G, Bommareddy PK, Bonilla DL, Borchers CH, Church SE, Ciliberto G, Cogdill AP, Fattore L, Hacohen N, Haris M, Lacasse V, Lie WR, Mehta A, Ruella M, Sater S, Spatz A, Taouli B, Tarhoni I, Gonzalez-Kozlova E, Tirosh I, Wang X, Gnjatic S. The Society for Immunotherapy of Cancer Perspective on Liquid Biopsy- and Radiomics-Based Technologies for Immuno-oncology Biomarker Discovery and Application. Clin Cancer Res. 2025 Jun 13; 31(12):2278-2293.